Etoricoxib
| Code | Size | Price |
|---|
| CDX-E0092-M025 | 25 mg | £63.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
L-791,456; MK-0663; MK 663; 5-Chloro-3-[4-(methylsulfonyl)phenyl]-2-(2-methyl-5-pyridinyl)pyridine; 5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine
Appearance:
White to off-white powder.
CAS:
202409-33-4
Class:
6.1
EClass:
32160000
Form (Short):
solid
GHS Symbol:
GHS06
Handling Advice:
Protect from light and moisture.
Hazards:
H302-H310
InChi:
InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
InChiKey:
MNJVRJDLRVPLFE-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 202409-33-4. Formula: C18H15ClN2O2S. MW: 358.84. Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) and a potent cyclooxygenase-2 (COX-2) inhibitor. This dipyridinyl compound demonstrates high in vitro and ex vivo selectivity for COX-2 over COX-1 in several assays. Used to treat patients suffering from osteoarthritis and rheumatoid arthritis. Might have some chemopreventive properties.
MDL:
MFCD06797512
Molecular Formula:
C18H15ClN2O2S
Molecular Weight:
358.84
Package Type:
Vial
PG:
II
Precautions:
P280-P302 + P350-P310
Product Description:
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) and a potent cyclooxygenase-2 (COX-2) inhibitor. This dipyridinyl compound demonstrates high in vitro and ex vivo selectivity for COX-2 over COX-1 in several assays. Used to treat patients suffering from osteoarthritis and rheumatoid arthritis. Might have some chemopreventive properties.
Purity:
>99% (HPLC)
Signal Word:
Danger
SMILES:
ClC1=CN=C(C2=CN=C(C)C=C2)C(C3=CC=C(S(C)(=O)=O)C=C3)=C1
Solubility Chemicals:
Soluble in DMSO (10mg/ml).
Source / Host:
Synthetic.
Transportation:
Excepted Quantity
UN Nummer:
2811
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
References
(1) D. Riendeau, et al.; J. Pharmacol. Exper. Therap. 296, 558 (2001) | (2) P.L. McGeer, et al.; Exp. Gerontol. 37, 925 (2002) | (3) R. Chenevard, et al.; Circulation 107, 405 (2003) | (4) A. Dallob,et al.; J. Clin. Pharmacol. 43, 573 (2003) | (5) P. Patrignani, et al.; Expert Opin. Pharmacother. 4, 265 (2003) | (6) S.D. Martina, et al.; Ann. Pharmacother. 39, 854 (2005) | (7) T. Tanwar, et al.; Eur. J. Cancer Prev. 19, 280 (2010) | (8) T. Tanwar, et al.; Asian Pac. J. Cancer Prev. 11, 1329 (2010)